Hanna K.

Hanna K. currently serves as Manager of Clinical Pharmacology at Novo Nordisk since March 2025. Prior to this role, Hanna held positions as Principal Scientist II and Principal Scientist I at Novartis from January 2022 to March 2025, focusing on in vitro and in vivo pharmacology in neuroscience and rare disease drug discovery. At Pfizer, from September 2019 to December 2021, Hanna worked as a Postdoctoral Fellow investigating chemotherapy-related anorexia and weight loss neurocircuits. Hanna also completed a Postdoctoral Fellowship at the Children's Hospital of Philadelphia Research Institute, examining nitric oxide signaling in relation to metabolic disorders, and was a Graduate Research Assistant at The University of Alabama, where research focused on neurodegenerative disorders. Educational qualifications include a Ph.D. in Neurobiology and Neurosciences from The University of Alabama and a Master's degree in Toxicology and Physiology from Emporia State University.